 In Situ Hybridization, Fluorescence
"In Situ Hybridization, Fluorescence" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
| Descriptor ID |
D017404
|
| MeSH Number(s) |
E01.370.225.500.620.670.325.350 E01.370.225.750.600.670.325.350 E05.200.500.620.670.325.350 E05.200.750.600.670.325.350 E05.393.285.350 E05.393.661.475.350
|
| Concept/Terms |
In Situ Hybridization, Fluorescence- In Situ Hybridization, Fluorescence
- Hybridization in Situ, Fluorescent
- FISH Technique
- FISH Techniques
- Technique, FISH
- Techniques, FISH
- Fluorescent in Situ Hybridization
- FISH Technic
- FISH Technics
- Technic, FISH
- Technics, FISH
- Hybridization in Situ, Fluorescence
- In Situ Hybridization, Fluorescent
|
Below are MeSH descriptors whose meaning is more general than "In Situ Hybridization, Fluorescence".
Below are MeSH descriptors whose meaning is more specific than "In Situ Hybridization, Fluorescence".
This graph shows the total number of publications written about "In Situ Hybridization, Fluorescence" by people in this website by year, and whether "In Situ Hybridization, Fluorescence" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 2 | 1 | 3 | | 1994 | 0 | 2 | 2 | | 1995 | 0 | 7 | 7 | | 1996 | 0 | 2 | 2 | | 1997 | 0 | 2 | 2 | | 1998 | 0 | 5 | 5 | | 1999 | 0 | 6 | 6 | | 2000 | 0 | 6 | 6 | | 2001 | 0 | 4 | 4 | | 2002 | 0 | 3 | 3 | | 2003 | 0 | 11 | 11 | | 2004 | 1 | 9 | 10 | | 2005 | 1 | 8 | 9 | | 2006 | 0 | 14 | 14 | | 2007 | 0 | 12 | 12 | | 2008 | 2 | 14 | 16 | | 2009 | 0 | 16 | 16 | | 2010 | 2 | 12 | 14 | | 2011 | 1 | 7 | 8 | | 2012 | 1 | 6 | 7 | | 2013 | 1 | 14 | 15 | | 2014 | 0 | 6 | 6 | | 2015 | 4 | 10 | 14 | | 2016 | 1 | 7 | 8 | | 2017 | 1 | 5 | 6 | | 2018 | 3 | 6 | 9 | | 2019 | 2 | 6 | 8 | | 2020 | 1 | 2 | 3 | | 2021 | 0 | 6 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "In Situ Hybridization, Fluorescence" by people in Profiles.
-
Dumbovic G, Braunschweig U, Langner HK, Smallegan M, Biayna J, Hass EP, Jastrzebska K, Blencowe B, Cech TR, Caruthers MH, Rinn JL. Nuclear compartmentalization of TERT mRNA and TUG1 lncRNA is driven by intron retention. Nat Commun. 2021 06 03; 12(1):3308.
-
Katsushima K, Lee B, Kunhiraman H, Zhong C, Murad R, Yin J, Liu B, Garancher A, Gonzalez-Gomez I, Monforte HL, Stapleton S, Vibhakar R, Bettegowda C, Wechsler-Reya RJ, Jallo G, Raabe E, Eberhart CG, Perera RJ. The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas. Neuro Oncol. 2021 04 12; 23(4):572-585.
-
McLemore LE, Albarracin CT, Gruschkus SK, Bassett RL, Wu Y, Dhamne S, Yim I, Lin K, Bedrosian I, Sneige N, Chen H. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines. Breast Cancer Res Treat. 2021 May; 187(1):95-104.
-
Li F, Hu D, Dieter C, Ansong C, Sussel L, Orr G. Single Molecule-Based fliFISH Validates Radial and Heterogeneous Gene Expression Patterns in Pancreatic Islet ß-Cells. Diabetes. 2021 05; 70(5):1117-1122.
-
Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, Shapiro GI, Socinski MA, Murphy DA, Conte U, Tang Y, Wang SC, Wilner KD, Villaruz LC. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol. 2021 06; 16(6):1017-1029.
-
Guzewicz L, Howell S, Crerand CE, Umbaugh H, Nokoff NJ, Barker J, Davis SM. Clinical phenotype and management of individuals with mosaic monosomy X with Y chromosome material stratified by genital phenotype. Am J Med Genet A. 2021 05; 185(5):1437-1447.
-
Mok T, Peters S, Camidge DR, Noé J, Gadgeel S, Ou SI, Kim DW, Konopa K, Pozzi E, Liu T, Loftin IR, Williams C, Shaw AT. Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. J Thorac Oncol. 2021 02; 16(2):259-268.
-
Weisel K, Spencer A, Lentzsch S, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka A, Quach H, Munder M, Lee C, Barreto W, Corradini P, Min CK, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Casneuf T, DeAngelis N, Amin H, Ukropec J, Kobos R, Mateos MV. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. J Hematol Oncol. 2020 08 20; 13(1):115.
-
Han S, Tatman P, Mehrotra S, Wani S, Attwell AR, Edmundowicz SA, Brauer BC, Wagh MS, Hammad HT, Shah RJ. Combination of ERCP-Based Modalities Increases Diagnostic Yield for Biliary Strictures. Dig Dis Sci. 2021 04; 66(4):1276-1284.
-
Fehrenbacher L, Cecchini RS, Geyer CE, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2020 02 10; 38(5):444-453.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|